CD19 CAR-T cells do not target long-lived autoreactive plasma B cells, nor there is any evidence of its effect on DN2/3 subsets, which have been associated with ADA in SLE, which leaves open the possibility of future relapse (70, 71). The gene discussed is CD19; the disease is systemic lupus erythematosus.